TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TENAX THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.52+0.16 (+11.76%)
Close on Oct 19, 2026
- Market cap
- $77.32M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.16 (−77.26%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TENAX THERAPEUTICS, INC. reported revenue of $0 for the twelve months to Jun 30, 2026.
Revenue
$0
TTM Q2 2026
Operating income
-$68.61M
TTM Q2 2026
EPS, diluted
-$1.48
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $77.32M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.68
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$64.86M
- EPS, diluted
- -$1.48
- Book value per share
- $2.23
- Diluted shares
- 51M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$0
Gross profit
–
Operating income
-$68.61M
Net income
-$64.86M
EPS, diluted
-$1.48
Free cash flow
–
Reported periodTrailing twelve months